skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Topical nepafenac in the treatment of diabetic macular edema

Original Research

(3929) Views  (781) Full article downloads

Authors: David Callanan, Patrick Williams

Published Date October 2008 Volume 2008:2(4) Pages 689 - 692
DOI: http://dx.doi.org/10.2147/OPTH.S3965

David Callanan, Patrick Williams

Texas Retina Associates, Arlington, TX, USA

Purpose: To determine the safety and efficacy of topical nepafenac 0.1% in the treatment of diabetic macular edema.

Methods: A consecutive case series was performed of patients treated with nepafenac monotherapy twice daily for diabetic macular edema. Visual acuities (VA) at baseline and final visit were recorded. Foveal thickness, based on optical coherence tomography, was also recorded.

Results: Six eyes of 5 patients were included in this study. Median initial Snellen vision was 20/100 (range, 20/40–20/400). After a mean of 210 days (range, 182–259), median final VA was 20/75 (range, 20/40–20/400). Four eyes gained vision and two eyes maintained vision. Mean pre-treatment vision was 0.78 logMAR and final VA was 0.67 logMAR, for a statistically significant improvement (p < 0.05). Mean initial foveal thickness was 417 microns (range, 286–599). After a mean of 178 days (range, 91–259), mean foveal thickness was 267 microns (range, 158–423), showing a statistically significant improvement (p < 0.05). Each eye had an improvement in foveal thickness.

Conclusion: The results from these 6 eyes suggest that nepafenac 0.1% may have activity against diabetic macular edema and warrants further investigation.

Keywords: diabetes, diabetic macular edema, inflammation, macular edema, nepafenac, NSAIDs






 

Other articles by Dr David Callanan



Readers of this article also read:

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
Cystoid macular edema
Nonarteritic anterior ischemic optic neuropathy associated with chronic anemia: a case series of myelodysplastic syndrome patients
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
Low-dose aspirin as treatment for central serous chorioretinopathy
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK